3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
77
Carcinoma, Non-Small-Cell Lung
64
Lung Neoplasms
31
Hodgkin Disease
13
Lymphoma
11
Neoplasm Metastasis
10
Recurrence
8
Lymphoma, Non-Hodgkin
8
Prostatic Neoplasms
7
Neoplasms
7
Adenocarcinoma of Lung
7
Uterine Cervical Neoplasms
5
Sarcoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Mesothelioma, Malignant
4
Lymphoma, Large B-Cell, Diffuse
4
Breast Neoplasms, Male
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Burkitt Lymphoma
3
Brain Neoplasms
3
Waldenstrom Macroglobulinemia
2
Interventions
Vinorelbine
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metatropic dwarfism
×
Vinorelbine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts